This clinical trial focuses on patients who have experienced a biochemical recurrence after undergoing surgery for prostate cancer. Biochemical recurrence refers to the return of signs of prostate cancer, indicated by rising levels of a protein called PSA, after initial treatment. The study aims to compare two different approaches to treating this condition: conventional “salvage” radiotherapy and a more personalized treatment based on results from a specialized imaging test called PSMA PET/CT. This imaging test helps to identify specific areas where cancer may have returned, allowing for targeted treatment.

Participants in the study will receive either the standard radiotherapy or the individualized treatment. The individualized treatment involves using a special solution called 18F-PSMA-1007, which is injected into the body to help highlight cancer cells during the PSMA PET/CT scan. Another product used in the study is the Locametz 25 micrograms kit for radiopharmaceutical preparation, which contains a substance called gozetotide. Both treatments are administered through an injection into a vein.

The purpose of the study is to determine which treatment approach is more effective in preventing the progression of prostate cancer, as measured by PSA levels. Participants will be monitored over time to assess their response to treatment, including how long it takes for the cancer to spread, their overall survival, and their quality of life. The study will also track the time until any additional treatments are needed. This research is expected to provide valuable insights into the best ways to manage prostate cancer recurrence after surgery.